Skip to main content

Hemostatic Agents

Topical hemostatic agents applied to the surgical field to control bleeding that cannot be addressed by sutures, cautery, or simple pressure — typically diffuse oozing from raw surfaces, capillary bleeding, or venous bleeding on tissue that won't tolerate cautery. They are divided by mechanism into passive matrices (mechanically enhance clot formation) and active agents (direct biochemical effect on the coagulation cascade).

Mechanistic Classification​

Passive hemostatic matrices​

Porous or fibrous matrices that physically contact blood and platelets, promoting fibrin deposition and mechanical clot formation. Work independently of the patient's coagulation cascade to varying degrees.

Active hemostatic agents​

Contain thrombin or other active coagulation factors that directly catalyze fibrin formation. Work even in patients with impaired clotting cascades (heparinization, coagulopathy).

  • Topical thrombin (Evithrom, Recothrom) — bovine-, pooled-human-, or recombinant-sourced thrombin
  • FloSeal — flowable gelatin matrix combined with human thrombin (passive + active hybrid)

Combination / advanced sealing products​

Discussed under Tissue Sealants & Adhesives:

  • Fibrin sealants (Tisseel, Evicel) — fibrinogen + thrombin
  • Collagen-fibrinogen patches (TachoSil, Evarrest) — solid-phase fibrin sealant

Selection by Clinical Situation​

SituationFirst-line agent
Broad raw surface, diffuse oozing (renal bed, bladder trigone, pelvic sidewall)FloSeal
Venous bleeding on a pelvic sidewallSurgicel or FloSeal
Partial nephrectomy renal bedFloSeal + sliding-clip renorrhaphy[1]
Bone bleeding (pubic bone, sacrum)Bone wax (outside this section) or Gelfoam
Bleeding around a nerve where cautery is contraindicatedSurgicel or thrombin-soaked Gelfoam
Diffuse capillary ooze from flap donor bedArista AH or Surgicel
Bleeding in a patient on anticoagulationFloSeal or thrombin-augmented matrix (active agents outperform passive in impaired coagulation)
Peritoneum or serosa with persistent oozeThin Surgicel layer + gentle pressure
Urinary tract / mucosaAvoid persistent foreign-body matrices; use active agents sparingly; many surgeons avoid cellulose in direct urinary contact due to stone-nidus concern

Key Pitfalls​

Urinary tract contact​

  • Oxidized cellulose (Surgicel) and gelatin matrices can serve as stone nidi if left in direct contact with the urinary collecting system
  • In partial nephrectomy, place hemostatic agents on the parenchymal renal bed rather than within the calyceal reconstruction

Nerve compression​

  • FloSeal and Surgicel swell as they absorb fluid — can compress adjacent nerves or cause focal compression injury if packed against a nerve (e.g., lumbosacral trunk during pelvic dissection)
  • Use judiciously near neurovascular structures

Mass-effect / foreign body reaction​

  • Large volumes of Surgicel or gelatin matrices left in the body can produce organized granuloma mimicking tumor on surveillance imaging
  • Document the location and volume in the operative note

Thromboembolic risk from intravascular migration​

  • Thrombin-containing products should never be injected into a vessel — rare case reports of pulmonary embolism from intravascular thrombin

Cost Hierarchy (Approximate)​

AgentPer-unit cost
GelfoamLow ($10–30)
SurgicelLow–moderate ($30–80)
Arista AHModerate ($80–150)
Topical thrombin (recombinant)Moderate–high ($100–300)
FloSealHigh ($200–500)
Fibrin sealantsHigh ($300–600)
Collagen-fibrinogen patchesVery high ($700–1500)

See Also​

References​

1. Hidas G, Kastin A, Mullerad M, Shental J, Moskovitz B, Nativ O. Sutureless nephron-sparing surgery: use of albumin glutaraldehyde tissue adhesive (BioGlue). Urology. 2006;67(4):697–700. doi:10.1016/j.urology.2005.10.064